Wyanoke GroupASCO20: Maintenance Metronomic Capecitabine Extends DFS in TNBC
According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.